Importantly, these positive behavioral effects were also seen in APP/PS1 mice treated with a systemically administrable, blood–brain barrier‐permeable compound originally developed to target brain cancer (Haftchenary et al, 2013), indicating that available or novel drugs targeted at Stat3 or other mediators of astrogliosis are promising candidates for future preclinical and clinical AD trials. This evidence concerns the gene APP and Alzheimer disease.